{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:38:24Z","timestamp":1776353904959,"version":"3.51.2"},"reference-count":33,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: The study aimed to determine the levels of change of the markers related to radiographic progression, such as Dickkopf-1 (DKK-1), sclerostin (SOST), bone morphogenetic protein (BMP)-2 and -4, and interleukin (IL)-17 and -23, in ankylosing spondyloarthritis (AS) during anti-tumor necrosis factor alpha (TNF-\u03b1) treatment.\r\nPatients and methods: Fifty-three anti-TNF-\u03b1 na\u00efve AS patients (34 males, 19 females; median: 38 years; range, 20 to 52 years) refractory to conventional treatments meeting the modified New York criteria or Assessment of SpondyloArthritis International Society classification criteria were enrolled to this cross-sectional, controlled study between October 2015 and January 2017. Fifty healthy volunteers (35 males, 15 females; median: 36 years; range, 18 to 55 years) with similar age and sex characteristics were recruited. Serum DKK-1, BMP-2, BMP-4, SOST, IL-17, and IL-23 levels were measured in both groups. The serum levels of the markers were measured again after about two years (mean follow-up duration of 21.7\u00b16.4 months) in AS patients who started anti-TNF-\u03b1 treatment. Demographic, clinical characteristics, and laboratory parameters were recorded. The disease activity at the time of inclusion was assessed through the Bath Ankylosing Spondylitis Disease Activity Index.\r\nResults: Serum DKK-1, SOST, IL-17, and IL-23 levels in the AS group before anti-TNF-a treatment were significantly higher compared to the control group (p<\/jats:p>","DOI":"10.46497\/archrheumatol.2023.9974","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T07:04:24Z","timestamp":1675235064000},"page":"148-155","source":"Crossref","is-referenced-by-count":3,"title":["Anti-tumor necrosis factor alpha treatment does not influence serum levels of the markers associated with radiographic progression in ankylosing spondylitis"],"prefix":"10.5152","volume":"38","author":[{"family":"Ali Erhan \u00d6zdemirel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Serdar Can G\u00fcven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Alper Do\u011fanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Z\u00fchre Sar\u0131 S\u00fcrmeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ayla \u00d6zyuval\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mehmet Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Diana R\u00fcstemova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Selin Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ay\u015fe Peyman Yal\u00e7\u0131n Say\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"H\u00fcseyin Tutkak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"\u015eebnem Ataman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ 2006;333:581-5. doi: 10.1136\/bmj.38954.689583.DE.","DOI":"10.1136\/bmj.38954.689583.DE"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: Defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-5. doi: 10.1136\/ ard.2006.066415.","DOI":"10.1136\/ard.2006.066415"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011;63:2215-25. doi: 10.1002\/art.30393.","DOI":"10.1002\/art.30393"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Baum R, Gravallese EM. Bone as a target organ in rheumatic disease: Impact on osteoclasts and osteoblasts. Clin Rev Allergy Immunol 2016;51:1-15. doi: 10.1007\/s12016-015-8515-6.","DOI":"10.1007\/s12016-015-8515-6"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010;69:592-7. doi: 10.1136\/ard.2008.102046.","DOI":"10.1136\/ard.2008.102046"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012;32:2523-7. doi: 10.1007\/s00296-011-1981-0.","DOI":"10.1007\/s00296-011-1981-0"},{"key":"ref-7","unstructured":"Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, et al. Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port 2014;39:146-51."},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD. Serum levels of novel noggin and sclerostinimmune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 2014;73:1873-9. doi: 10.1136\/annrheumdis-2013-203630.","DOI":"10.1136\/annrheumdis-2013-203630"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Chen HA, Chen CH, Lin YJ, Chen PC, Chen WS, Lu CL, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol 2010;37:2126-32. doi: 10.3899\/ jrheum.100200.","DOI":"10.3899\/jrheum.100200"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Milanez FM, Saad CG, Viana VT, Moraes JC, P\u00e9rico GV, Sampaio-Barros PD, et al. IL-23\/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther 2016;18:52. doi: 10.1186\/s13075-016-0949-6.","DOI":"10.1186\/s13075-016-0949-6"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Kang YK, Zhang MC. IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. Genet Mol Res 2014;13:4673-9. doi: 10.4238\/2014.June.18.10.","DOI":"10.4238\/2014.June.18.10"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007;9:R96. doi: 10.1186\/ar2297.","DOI":"10.1186\/ar2297"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. doi: 10.1002\/ art.1780270401.","DOI":"10.1002\/art.1780270401"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009;68:777-83. doi: 10.1136\/ard.2009.108233.","DOI":"10.1136\/ard.2009.108233"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31. doi: 10.1136\/ard.2010.133645.","DOI":"10.1136\/ard.2010.133645"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Cici D, Corrado A, Rotondo C, Cantatore FP. Wnt signaling and biological therapy in rheumatoid arthritis and spondyloarthritis. Int J Mol Sci 2019;20:5552. doi: 10.3390\/ijms20225552.","DOI":"10.3390\/ijms20225552"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Descamps E, Molto A, Borderie D, Lories R, Richard CM, Pons M, et al. Changes in bone formation regulator biomarkers in early axial spondyloarthritis. Rheumatology (Oxford) 2021;60:1185-94. doi: 10.1093\/rheumatology\/keaa296.","DOI":"10.1093\/rheumatology\/keaa296"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Zhang L, Ouyang H, Xie Z, Liang ZH, Wu XW. Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: A meta-analysis. Exp Mol Med 2016;48:e228. doi: 10.1038\/emm.2016.12.","DOI":"10.1038\/emm.2016.12"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-8. doi: 10.1002\/art.27231.","DOI":"10.1002\/art.27231"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63. doi: 10.1038\/nm1538.","DOI":"10.1038\/nm1538"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 2015;74:1387-93. doi: 10.1136\/annrheumdis-2013-204835.","DOI":"10.1136\/annrheumdis-2013-204835"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-54. doi: 10.1002\/art.38070.","DOI":"10.1002\/art.38070"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62. doi: 10.1002\/art.24888.","DOI":"10.1002\/art.24888"},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, et al. Low sclerostin levels: A predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012;14:R216. doi: 10.1186\/ar4055.","DOI":"10.1186\/ar4055"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. doi: 10.1172\/JCI23738.","DOI":"10.1172\/JCI23738"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Bleil J, Sieper J, Maier R, Schlichting U, Hempfing A, Syrbe U, et al. Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: Implications for joint remodeling in AS. Arthritis Res Ther 2015;17:170. doi: 10.1186\/s13075-015-0675-5.","DOI":"10.1186\/s13075-015-0675-5"},{"key":"ref-27","doi-asserted-by":"crossref","unstructured":"Yang M, Yuan H, Miao M, Xu W. The osteogenic potential of ligament fibroblasts is greater in ankylosing spondylitis patients than in patients with osteoarthritis. Z Rheumatol 2015;74:340-5. doi: 10.1007\/s00393- 014-1394-z.","DOI":"10.1007\/s00393-014-1394-z"},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. doi: 10.1172\/JCI23738.","DOI":"10.1172\/JCI23738"},{"key":"ref-29","unstructured":"Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T. Induction of abundant osteoclastlike multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 1998;13:751-9. doi: 10.14670\/ HH-13.751."},{"key":"ref-30","doi-asserted-by":"crossref","unstructured":"Rossini M, Viapiana O, Adami S, Idolazzi L, Fracassi E, Gatti D. Focal bone involvement in inflammatory arthritis: The role of IL17. Rheumatol Int 2016;36:469- 82. doi: 10.1007\/s00296-015-3387-x.","DOI":"10.1007\/s00296-015-3387-x"},{"key":"ref-31","doi-asserted-by":"crossref","unstructured":"Appel H, Maier R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013;65:1522-9. doi: 10.1002\/art.37937.","DOI":"10.1002\/art.37937"},{"key":"ref-32","doi-asserted-by":"crossref","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345- 52. doi: 10.1172\/JCI5703.","DOI":"10.1172\/JCI5703"},{"key":"ref-33","doi-asserted-by":"crossref","unstructured":"Daoussis D, Kanellou A, Panagiotopoulos E, Papachristou D. DKK-1 is underexpressed in mesenchymal stem cells from patients with ankylosing spondylitis and further downregulated by IL-17. Int J Mol Sci 2022;23:6660. doi: 10.3390\/ ijms23126660.","DOI":"10.3390\/ijms23126660"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1324\/2340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1324\/2341","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1324\/2340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:03:22Z","timestamp":1761210202000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2023.9974","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}